Patents Examined by Stacy S. Brown
-
Patent number: 6482412Abstract: A novel compound, which is effective for treatment of AIDS and has inhibitory activity on human immunodeficiency viruses (HIV), was examined. The K97-0003 peptide, which has anti-HIV activity caused by inhibition of syncytium formation by fusion of envelope glycoprotein of HIV and the host cells expressing the receptor to said virus, was provided by the present invention. Furthermore, the base sequence of the gene coding for said polypeptide, and the method for preparing said polypeptide using strain K97-0003 were provided.Type: GrantFiled: January 24, 2001Date of Patent: November 19, 2002Assignees: Gakkou Houjin Kitasato Gakuen, Japan Society for the Promotion of ScienceInventors: Haruo Tanaka, Satoshi Ohmura
-
Patent number: 6472206Abstract: The present invention provides methods and compositions for the in situ growth, freezing and testing of cultured cells. In particular, the present invention provides methods and compositions for the long-term preservation of cells in ready-to-use formats for testing. In addition, the present invention provides rapid and easy to use means to diagnose viral and other infections. Furthermore, the present invention provides easy to use means to grow and store cells in situ for testing methods. Indeed, the present invention makes viral, chlamydial and other diagnostic methods accessible to small laboratories, including those without cell culture capabilities.Type: GrantFiled: April 28, 2000Date of Patent: October 29, 2002Assignees: Interthyr Corporation, Diagnostic Hybrids, Inc.Inventors: David R. Scholl, Francesco Saverio Ambesi-Impiombato, James L. Brown, Leonard D. Kohn, Joseph A. Jollick, Jr.
-
Patent number: 6468534Abstract: A non-mammalian transfer factor, compositions including the non-mammalian transfer factor, and methods for generating and preparing the non-mammalian transfer factor. The non-mammalian transfer factor may have specificity for one or more antigens. A method of using the non-mammalian transfer factor includes administering either antigen-specific non-mammalian transfer factor or antigen non-specific non-mammalian transfer factor to mammals to treat or prevent pathogenic infections in the mammals.Type: GrantFiled: September 21, 2000Date of Patent: October 22, 2002Assignee: 4Life Research, LCInventors: William J. Hennen, David T. Lisonbee
-
Patent number: 6468526Abstract: Disclosed are novel isolated strains of bacteria of the genus Lactobacillus which are useful in a vaginal medicant. Also disclosed are medicants containing such Lactobacilli, a novel preservation matrix for microorganisms, a method for preserving microbial cells within a medicant, and methods for preventing and treating vaginal and gastrointestinal infections.Type: GrantFiled: December 21, 2001Date of Patent: October 22, 2002Assignee: GyneLogix, Inc.Inventor: Gerald L. Chrisope
-
Patent number: 6461809Abstract: The present invention relates to cells which have improved receptivity to viruses which are capable of infecting them. Receptivity to such viruses is improved by selecting cells from a population which express the receptor(s) that enable a virus to attach to the cell and gain entry into it. Any combination of viruses and host cell lines can be used. In a preferred embodiment, the present invention relates to improving receptivity or infectivity of a cell line which can be infected with an immunodeficiency virus, such as HIV-1.Type: GrantFiled: April 27, 1999Date of Patent: October 8, 2002Assignee: Bio-Tech Imaging, INCInventors: Robert A. Hallowitz, Susan Young, Chester King
-
Patent number: 6461616Abstract: Disclosed herein is a vaccine which provides immunity to mammals from infection and/or disease caused by a lentivirus, such as equine infectious anemia virus, human immunodeficiency virus (HIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) or simian immunodeficiency virus (SIV) said composition comprising a deletion in a gene that blocks replication of the virus in vivo. Preferably said composition encompasses at least one deletion in a lentivirus which provides protection from exposure to wild-type lentiviruses. It also encompasses a marker vaccine in which a foreign gene is inserted into the gene-deleted region, said inserted gene providing a diagnostic tool for use in vaccinated mammals. The scope of the invention encompasses an EIAV vaccine that allows equines to be safely vaccinated and protected from disease without converting to a seropositive status on the Coggin's Test or any other test which measures p26.Type: GrantFiled: September 9, 2000Date of Patent: October 8, 2002Assignee: Akzo Nobel NVInventors: Ronald Montelaro, Jodi Craigo, Charles Issel, Bridget Puffer, Kristina J. Hennessy, Karen K Brown
-
Patent number: 6455265Abstract: A method of searching for and obtaining a vaccine against the pathogenic effects related to the infection of an animal or human host by a retrovirus that penetrates into a target cell of the host, and a vaccine obtained by the method are provided. The method includes preparing candidate vaccine agents based on a polypeptide comprising at least part of an envelope protein of a pathogenic strain of the retrovirus and selecting as the vaccine a modified polypeptide chosen from polypeptides that induces an immune response directed against an immunodominant region of an envelope protein of the retrovirus and not against a protein of the host.Type: GrantFiled: May 15, 2000Date of Patent: September 24, 2002Assignee: Mymetics S.A.Inventor: Pierre-François Serres
-
Patent number: 6448070Abstract: A fusion capsid protein comprising a plant virus capsid protein fused to an antigenic polypeptide is used as a molecule for presentation of that polypeptide to the immune system of an animal such as a human. The plant virus capsid protein is that of an alfalfa mosaic virus (AlMV) or ilarvirus.Type: GrantFiled: February 25, 1999Date of Patent: September 10, 2002Assignee: Thomas Jefferson UniversityInventors: Hilary Koprowski, Vidadi Yusibov, Douglas Craig Hooper, Anna Modelska
-
Patent number: 6447989Abstract: A method is disclosed for diagnosing early stage of a disease in which an intact protein found in urine is an indicator of the disease. The method includes assaying urine sample to detect the presence of modified protein using either immunological or non-immunological technique. Methods for preventing and treating the disease are also disclosed.Type: GrantFiled: October 12, 1999Date of Patent: September 10, 2002Assignee: Monash UniversityInventor: Wayne D. Comper
-
Patent number: 6447993Abstract: The subject invention pertains to novel methods and compositions for protecting cats from infection by a broad range of FIV strains using a multi-subtype FIV vaccine. Multi-subtype FIV vaccines comprising either cell free whole virus or cell lines infected with viruses are described. Methods for vaccinating cats with the subject vaccine compositions are also described. Cats vaccinated according to the methods and compositions of the subject invention exhibit protective humoral and cellular immune responses to FIV when challenged with homologous or heterologous strains of FIV. The subject invention also pertains to novel feline cell lines that are susceptible to infection by FIV and their methods of use.Type: GrantFiled: October 1, 1997Date of Patent: September 10, 2002Assignees: University of Florida Research Foundation, Inc.,, Regents of the University of CaliforniaInventor: Janet K. Yamamoto
-
Patent number: 6432633Abstract: An immunoassay method of the HIV-1p24 antigen by sandwich method, using at least one polyclonal antibody recognizing the HIV-1p24 antigen and at least two monoclonal antibodies recognizing the HIV-1p24 antigen, is provided together with a reagent therefor, to establish more highly sensitive assay of the HIV-1p24 antigen than conventionally.Type: GrantFiled: July 21, 2000Date of Patent: August 13, 2002Assignee: Fujirebio Kabushiki KaishaInventors: Katsuhiko Yamamoto, Akemi Yoshiki, Toshio Matsui, Atsushi Umetani
-
Patent number: 6432632Abstract: A fluorescence polarization method for analyzing an assay-object in a sample is provided. The fluorescence polarization method includes the steps of: (a) providing a fluorescent-labeled protein in which a protein is covalently bound to a fluorochrome(s), wherein the protein is capable of specifically binding to the assay-object; (b) allowing the fluorescent-labeled protein to bind to the assay-object; and (c) measuring a change in the degree of fluorescence polarization which has taken place in the fluorescent-labeled protein by its binding to the assay-object.Type: GrantFiled: July 23, 1999Date of Patent: August 13, 2002Assignee: Matsushita Electric Industrial Co., Ltd.Inventors: Hiroshi Nakayama, Jinsei Miyazaki
-
Patent number: 6429298Abstract: The present invention provides for various screening assays which are amenable to high throughput formats and identify a variety of useful mutations in tumor suppressor genes such as p53. Such mutations include those that activate the molecule, increase thermostability, increase transcriptional activity and facilitate resistance to inhibitory molecules. Also provided are methods of screening for accessory proteins that interact with tumor suppressors in both inhibitory and activating fashions, as well as cleavable mutants of p53 that are activated by viral proteases.Type: GrantFiled: October 13, 1999Date of Patent: August 6, 2002Assignee: Board of Regents, The University of Texas SystemInventors: Andrew D. Ellington, Ichiro Matsumura
-
Patent number: 6410023Abstract: Recombinant parainfluenza virus (PIV) are provided in which expression of the C, D and/or V translational open reading frame(s) (ORFs) is reduced or ablated to yield novel PIV vaccine candidates. Expression of the C, D and/or V ORF(s) is reduced or ablated by modifying a recombinant PIV genome or antigenome, for example by introduction of a stop codon, by a mutation in an RNA editing site, by a mutation that alters the amino acid specified by an initiation codon, or by a frame shift mutation in the targeted ORF(s). Alternatively, the C, D and/or V ORF(s) is deleted in whole or in part to render the protein(s) encoded thereby partially or entirely non-functional or to disrupt protein expression altogether. C, D and/or V ORF(s) deletion and knock out mutants possess highly desirable phenotypic characteristics for vaccine development. These deletion and knock out mutations changes specify one or more desired phenotypic changes in the resulting virus or subviral particle.Type: GrantFiled: July 9, 1999Date of Patent: June 25, 2002Assignee: United States of AmericaInventors: Anna P. Durbin, Peter L. Collins, Brian R. Murphy
-
Patent number: 6406861Abstract: Methods of reducing pre-existing humoral immunity to a viral immunogenic therapeutic agent such as adenovirus, using immunoapheresis are disclosed. Antibodies specific for the viral immunogenic therapeutic agent are selectively removed from the blood of an individual prior to administration of the viral immunogenic therapeutic agent by reaction extracorporeally with an immunosorbent which specifically binds the antibody. After the antibody is selectively removed from the blood, the blood is reinfused into the patient and the viral immunogenic therapeutic agent is administered. The invention also provides kits and compositions for selective removal of anti-viral antibody.Type: GrantFiled: October 6, 1999Date of Patent: June 18, 2002Assignee: Cell Genesys, Inc.Inventors: Daniel R. Henderson, Yu Chen, De Chao Yu
-
Patent number: 6403363Abstract: A method for preventing or reducing bacterial contamination of a viral vaccine is disclosed. The method comprises adding an effective preserving amount of a polybiguanide-containing preservative composition to a solution containing vaccine virus or virus antigen. The method is particularly useful in preventing or reducing bacterial contamination of process solutions involved in the manufacture of influenza vaccines.Type: GrantFiled: July 12, 2001Date of Patent: June 11, 2002Assignee: Medeva Europe LimitedInventors: Michelle Irene Gregarach Lawrence, Declan Greally
-
Patent number: 6403301Abstract: The invention allows, for the first time, to (almost) perfectly detect the various phases of a BDV infection in all species by combining a newly discovered test parameter, the circulating immune complexes (CICs) in the blood plasma, with already known parameters, antigen (AG) in white blood cells and antibodies (AK) in the plasma. All three parameters can be determined from a single blood sample. The detection of BDV-specific CICs described for the first time by the invention as the only infection markers with long-time persistence allows both the detection of healthy carriers (latent infections) and the evaluation of the development of the infection and of therapy results in the case of diseased individuals.Type: GrantFiled: June 29, 2000Date of Patent: June 11, 2002Inventors: Hans Ludwig, Liv Bode
-
Patent number: 6399067Abstract: A composition which elicits antibodies to multiple known variants of Tat protein of HIV-1 of both the B and non-B clades contains the peptide R1-Asp-Pro-Asn-Leu-Asp-Pro-Trp-Asn-R2 SEQ ID NO: 23, and preferably an additional at least two variants of a peptide or polypeptide of the formula: R1-Asp-Pro-Y7-Leu-Glu-Pro-Trp-Z12-R2 SEQ ID NO: 8. In this composition, at least one of the two variants contains Arg at Y7 and Lys at Z12, and in at least a second of the two variants Y7 is Asn and Z12 is Asn. Vaccinal and pharmaceutical compositions can contain one or more such peptides associated with carrier proteins, associated in multiple antigenic peptides, or as part of recombinant proteins. Diagnostic compositions and uses are described for assessing the immune status of vaccinated patients.Type: GrantFiled: April 28, 2000Date of Patent: June 4, 2002Assignee: Thymon L.L.C.Inventor: Gideon Goldstein
-
Patent number: 6395561Abstract: A lipid bilayer with affinity to an analyte, which directly signals binding by a changes in the light absorption spectra. This novel assay means and method has special applications in the drug development and medical testing fields. Using a spectrometer, the system is easily automated, and a multiple well embodiment allows inexpensive screening and sequential testing. This invention also has applications in industry for feedstock and effluent monitoring.Type: GrantFiled: December 14, 1999Date of Patent: May 28, 2002Assignee: Regents of the University of CaliforniaInventors: Deborah Charych, Jon Nagy, Wayne Spevak
-
Patent number: 6383488Abstract: The present invention relates to five synthetic peptides of pre-M/M protein of Dengue-2 virus, corresponding to amino acid sequences 3-31, 45-67, 57-92, 69-93 and 103-124. The anti-peptide immune response was evaluated in mice. Recombinant fusion proteins were also obtained, including regions of pre-M/M protein. The presence of B cell epitopes in both mice and humans was demonstrated in the pre-M/M protein peptides. Peptides 3-31 and 103-124 elicited neutralizing antibodies against the four serotypes of Dengue virus. Virus-specific proliferative responses were demonstrated in mice immunized with non-conjugated peptides 3-31 and 57-92. Mice immunized with conjugated peptides 3-31, 57-92, and 69-93 were protected when they were challenged with Dengue-2 virus. Thus, the presence of sequential epitopes in Pre-M/M protein of Dengue-2 virus was demonstrated, as well as their relevance in the immune response against this flavivirus.Type: GrantFiled: October 14, 1999Date of Patent: May 7, 2002Assignees: Centro de Ingeniera Genetic Y Biotechnologies (CIGB), Instituto de Medicina Tropical “Pedro Kouri”Inventors: Susana Vazquez Ramudo, Guadalupe Guzman Tirado, Gerardo Enrique Guillen Nieto, Orlando Luis Pardo Lazo, Glay Chinea Santiago, Ana Beatriz Perez Diaz, Maritza Pupo Antunez, Rosmari Rodriguez Roche, Osvaldo Reyes Acosta, Hilda Elisa Garay Perez, Gabriel Padron Palomares, Maylin Alvarez Vera, Luis Morier Diaz, Omaida Perez Insuita, Jose Luis Pelegrino Martinez De La Cotera